IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by abrdn plc

abrdn plc boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 138.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,151 shares of the medical research company's stock after purchasing an additional 62,776 shares during the quarter. abrdn plc owned about 0.06% of IQVIA worth $25,024,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of IQV. International Assets Investment Management LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at $13,759,000. Schwartz Investment Counsel Inc. raised its position in shares of IQVIA by 4.1% during the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company's stock valued at $41,345,000 after buying an additional 7,050 shares in the last quarter. Dfpg Investments LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at $1,106,000. Sei Investments Co. raised its position in shares of IQVIA by 20.2% during the 3rd quarter. Sei Investments Co. now owns 94,748 shares of the medical research company's stock valued at $18,641,000 after buying an additional 15,913 shares in the last quarter. Finally, Duality Advisers LP purchased a new stake in shares of IQVIA during the 3rd quarter valued at $491,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the business's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 1,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company's stock, valued at $5,031,894. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. Insiders own 1.60% of the company's stock.

IQVIA Stock Up 0.9 %

NYSE IQV traded up $2.22 during trading hours on Wednesday, reaching $240.84. 1,492,788 shares of the company's stock traded hands, compared to its average volume of 972,338. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The firm has a market cap of $43.71 billion, a PE ratio of 33.04, a PEG ratio of 2.24 and a beta of 1.50. The firm has a 50-day simple moving average of $245.55 and a 200 day simple moving average of $222.56. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.54 earnings per share. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IQV. Guggenheim lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. BTIG Research began coverage on shares of IQVIA in a report on Tuesday, February 13th. They set a "buy" rating and a $285.00 target price on the stock. StockNews.com raised shares of IQVIA from a "hold" rating to a "buy" rating in a report on Friday, February 16th. Barclays raised their price target on shares of IQVIA from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Thursday, February 15th. Finally, SVB Leerink began coverage on shares of IQVIA in a report on Monday, February 26th. They issued an "outperform" rating and a $290.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.